Organization

Huntsman Cancer Center

1 abstract

2 posters

Poster

First-in-human study of BLU-554, a potent, highly selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation

Poster

First-in-human study of BLU-554, a potent, highly selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation

Abstract

A phase 2 multi-arm study of magrolimab in combination with docetaxel in patients with locally advanced or metastatic solid tumors: ELEVATE Lung and UC.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Rogel Cancer Center, University of Michigan, Huntsman Cancer Center, Oregon Health and Science University, Hospital Virgen del Rocio, Seville, Spain,